The DOI matches its Crossref record.
Incidence of Invasive Breast Cancer by Hormone Receptor Status From 1992 to 1998
Abstract
Purpose: Between 1987 and 1998, breast cancer incidence rates rose 0.5%/yr in the United States. A question of potential etiologic and clinical importance is whether the hormone receptor status of breast tumors is also changing over time. This is because hormone receptor status may reflect different etiologic pathways and is useful in predicting response to adjuvant therapy and prognosis. Methods: Age-adjusted, age-specific breast cancer incidence rates by estrogen receptor (ER) and progesterone receptor (PR) status from 1992 to 1998 were obtained and compared from 11 population-based cancer registries in the United States that participate in the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program. Results: From 1992 to1998, the overall proportion of breast cancers that were ER-positive and PR-positive increased from 75.4% to 77.5% (P = .0002) and from 65.0% to 67.7% (P < .0001), respectively, continuing trends observed before 1992. These increases were limited to women 40 to 69 years of age. The proportions of ER-positive/PR-positive tumors increased from 56.7% to 62.3% (P = .0010) among 40- to 49-year-olds, from 58.0% to 63.2% (P = .0002) among 50- to 59-year-olds, and from 63.2% to 67.9% (P = .0020) among 60- to 69-year-olds. Conclusion: From 1992 to 1998, the proportion of tumors that are hormone receptor–positive rose as the proportion of hormone receptor–negative tumors declined. Because the incidence rates of hormone receptor–negative tumors remained fairly constant over these years, the overall rise in breast cancer incidence rates in the United States seems to be primarily a result of the increase in the incidence of hormone receptor–positive tumors. Hormonal factors may account for this trend.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Fan, L., Strasser-Weippl, K., Li, J.-J., St Louis, J., Finkelstein, D. M., Yu, K.-D., Chen, W.-Q., Shao, Z.-M., & Goss, P. E. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70567-9 · Cited by 1,397
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Pöstlberger, S., Menzel, C., Jakesz, R., Seifert, M., Hubalek, M., Bjelic-Radisic, V., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806285 · Cited by 1,025
Key steps for effective breast cancer prevention
Britt, K. L., Cuzick, J., & Phillips, K.-A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0266-x · Cited by 992
Dunnwald, L. K., Rossing, M. A., & Li, C. I. (2007) · Breast Cancer Research · doi:10.1186/bcr1639 · Cited by 785
Self-citationEtiology of Hormone Receptor–Defined Breast Cancer: A Systematic Review of the Literature
Althuis, M. D., Fergenbaum, J. H., Garcia-Closas, M., Brinton, L. A., Madigan, M. P., & Sherman, M. E. (2004) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.1558.13.10 · Cited by 628
Kesson, E. M., Allardice, G. M., George, W. D., Burns, H. J. G., & Morrison, D. S. (2012) · BMJ · doi:10.1136/bmj.e2718 · Cited by 579
The Effects of Tibolone in Older Postmenopausal Women
Cummings, S. R., Ettinger, B., Delmas, P. D., Kenemans, P., Stathopoulos, V., Verweij, P., Mol-Arts, M., Kloosterboer, L., Mosca, L., Christiansen, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800743 · Cited by 457
The molecular pathology of breast cancer progression
Bombonati, A., & Sgroi, D. C. (2011) · The Journal of Pathology · doi:10.1002/path.2808 · Cited by 455
Linden, H. M., Stekhova, S. A., Link, J. M., Gralow, J. R., Livingston, R. B., Ellis, G. K., Petra, P. H., Peterson, L. M., Schubert, E. K., Dunnwald, L. K., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3810 · Cited by 394
Soy, isoflavones, and breast cancer risk in Japan
Yamamoto, S., Sobue, T., Kobayashi, M., Sasaki, S., & Tsugane, S. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.12.906 · Cited by 391
“women ( 41 ) may also explain the discrepancy between Japanese and Western countries in incidence among older age groups.”
BackgroundGoetz, M. P., Sangkuhl, K., Guchelaar, H., Schwab, M., Province, M., Whirl‐Carrillo, M., Symmans, W. F., McLeod, H. L., Ratain, M. J., Zembutsu, H., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1007 · Cited by 336
Parise, C. A., Bauer, K. R., Brown, M. M., & Caggiano, V. (2009) · The Breast Journal · doi:10.1111/j.1524-4741.2009.00822.x · Cited by 331
Robertson, S., Azizpour, H., Smith, K., & Hartman, J. (2018) · Translational Research · doi:10.1016/j.trsl.2017.10.010 · Cited by 295
Obesity and Cancer: Local and Systemic Mechanisms
Iyengar, N. M., Hudis, C. A., & Dannenberg, A. J. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-050913-022228 · Cited by 281
Effects of young age at presentation on survival in breast cancer
El Saghir, N. S., Seoud, M., Khalil, M. K., Charafeddine, M., Salem, Z. K., Geara, F. B., & Shamseddine, A. I. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-194 · Cited by 268
Menopause is a determinant of breast adipose inflammation
Iyengar, N. M., Morris, P. G., Zhou, X. K., Gucalp, A., Giri, D., Harbus, M. D., Falcone, D. J., Krasne, M. D., Vahdat, L. T., Subbaramaiah, K., et al. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0243 · Cited by 106
Cho, Y. A., Kim, J., Park, K.-S., Lim, S.-Y., Shin, A., Sung, M.-K., & Ro, J. (2010) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2010.95 · Cited by 69
Metadata
- Authors
- Li, C. I., Daling, J. R., & Malone, K. E.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-01-01
- Volume
- 21
- Issue
- 1
- Pages
- 28-34
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2163134191
- Cited by
- 245
- References
- 0
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.